Key milestone for OXC-201 – patent approval in Japan

The patent for OXC-201, Oxcias potential breakthrough approach for the treatment of IPF (idiopathic pulmonary fibrosis), has recently been approved in Japan. It is the first country in which the patent has been approved and is a very important milestone. Japan and Asia in general are major markets for OXC-201. Asia is estimated to have the largest number of cases of pulmonary fibrosis in the world.

Additional national and regional patent applications are pending in the US, Europe (EPO – European Patent Organization), China and Canada.

As previously communicated, the EIC (European Innovation Council) awarded Oxcia AB in early 2023 a grant of 2.5 million euros within the EIC-Transition program for the next phase of the development of OXC-201.


About OXC-201

OXC-201 is a small molecule inhibitor of OGG1. By targeting the DNA repair enzyme OGG1 (8-oxo guanine DNA glycosylase-1), OXC-201 inhibits binding of OGG1 to DNA and thereby the modulation of gene transcription. OGG1 plays a significant role in modulating inflammation and fibrogenesis; genetic downregulation or chemical inhibition of OGG1 has been shown to protect against inflammation and fibrosis in several experimental disease models.

For more information, please contact:


Christina Kalderén, Pre-clinical Director



Ulrika Warpman Berglund, CEO



Briefly about Oxcia

Oxcia AB conducts innovative research through its unique way of utilizing oxidative DNA damage and DNA Damage response(1) and develops novel, safe and effective treatments for patients suffering from cancer, inflammation or fibrosis. Oxcia currently has two drug candidates, both with first-in-class potential. OXC-101 is in early clinical development for the treatment of solid and hematological cancers. OXC-201 is being developed as a treatment for inflammation and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.

More information about Oxcia is available at

(Note (1): DNA Damage Response, DDR – the body's processes to in various ways repair the damage that occurs to DNA)